ProBioGen enters into an agreement with Nobelpharma for the development of the manufacturing process of their vaccine project


BERLIN, Germany, March 24, 2021 / B3C News Wire / – ProBioGen AG is delighted to announce the signing of a service agreement for Nobelpharma’s highly relevant vaccine project.

Previous work has already confirmed the versatility and benefits of ProBioGen’s vaccine development platform, consisting of the patented and proven AGE1.CR.pIX® suspension cell line and its high performance cell culture medium, for the spread of the viral strain of Nobelpharma.

Now, ProBioGen applies cutting-edge technologies and deep expertise to perform upstream and downstream process development of Nobelpharma’s highly relevant vaccine for large-scale manufacturing.

The AGE1.CR.pIX duck cell line has been designed for use in industrial GMP-compliant production of a wide variety of viruses in large bioreactors and is free of any adventitious agents.

It has already proven its great utility for the production of viral vectors in various clinical trials.

About ProBioGen
ProBioGen is a contract development and manufacturing (CDMO) organization and technology provider with extensive expertise in cell line engineering, process development and GMP manufacturing of biopharmaceuticals.

Our proprietary technologies such as CHO.RiGHT®, GlymaxX® glyco-genetic engineering and DirectedLuck ™ targeted transposase, combined with our efficient process development and robust GMP manufacturing, accelerate and advance the development of drug candidates, initial concept for industrial marketing. .

ProBioGen provides modern manufacturing solutions for viral vectors with its continuous duck cell line AGE1.CR®, a vaccine platform with MVA-CR19 and provides technological support for gene therapy and vaccine development.

All services and technologies are integrated into a total quality management system to ensure compliance with international ISO and GMP (EMA / FDA) standards.

ProBioGen has been successfully serving international clients for over 26 years, is a private company based in Berlin.


Dr Gabriele Schneider
This e-mail address is protected from spam. You need JavaScript enabled to view it.
+49 (0) 30 3229 35 100

Keywords: cell line; Cell culture techniques; Cultural media; Bioreactors; Cell proliferation; Development of cell lines; Cultured cells; virus; Vaccines; Organic Products; Productivity; Technology; Trade; Germany

Posted by B3C News Wire


Leave A Reply